Glucagon-like peptide-1 (GLP-1) agonist therapies are increasingly being used for type 2 diabetes and obesity, but evidence now shows they also reduce inflammation across multiple organs through mechanisms related and unrelated to weight-loss-driven metabolic improvements
Weight loss outcomes depend on dose, diet, exercise, and adherence to the protocol
Membrane transporter mainly comprised multidrug and toxic extrusion (MATE) transporters and ATP binding cassette (ABC) protein transporters (Marinova et al., 2007
GLP-1 reduces endoplasmic reticulum stress and apoptosis induced by hyperglycaemia and regulates mitochondrial function via stimulation of optic atrophy protein 1 [69]
As of April 2026, compounded GLP-1 medications remain available through certain pharmacy pathways, though the landscape has contracted compared to 2023 and 2024 following regulatory changes
This is based on animal studies that showed using the medication in pregnancy was associated with pregnancy loss as well as an increased rate of birth defects